{"organizations": [], "uuid": "2ed40bc5076a8c03a06b84ec76deab53b05a52c0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180119.html", "section_title": "Archive News &amp; Video for Friday, 19 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-albireo-pharma-says-elobixibat-app/brief-albireo-pharma-says-elobixibat-approved-in-japan-for-treatment-of-chronic-constipation-idUSFWN1PE0SH", "country": "US", "domain_rank": 408, "title": "BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.98, "site_type": "news", "published": "2018-01-19T21:12:00.000+02:00", "replies_count": 0, "uuid": "2ed40bc5076a8c03a06b84ec76deab53b05a52c0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-albireo-pharma-says-elobixibat-app/brief-albireo-pharma-says-elobixibat-approved-in-japan-for-treatment-of-chronic-constipation-idUSFWN1PE0SH", "ord_in_thread": 0, "title": "BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation", "locations": [], "entities": {"persons": [{"name": "elobixibat", "sentiment": "none"}], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "albireo pharma inc", "sentiment": "negative"}, {"name": "brief-albireo pharma says elobixibat", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "albireo pharma", "sentiment": "none"}, {"name": "ea pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (Reuters) - Albireo Pharma Inc:\n* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS\n* ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION\n* ALBIREO PHARMA - JAPAN‘S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN\n* ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD\n* ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-19T21:12:00.000+02:00", "crawled": "2018-01-20T17:32:33.018+02:00", "highlightTitle": ""}